You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
Our in-house aseptic fill-finish capabilities using our U.S. Food and Drug Administration (FDA)-approved process offers clinical stage and commercial clients the speed and flexibility demanded to meet the needs of caregivers and patients. Our program offers a wide variety of container closure formats as well the ability to fill and finish different total volumes and presentation sizes for your production requirements. Our aseptic filling process utilizes a state-of-the-art closed isolator design, allowing for the removal of human interventions and providing safe drug products for patients.
Leverage our fill-finish capabilities to enhance each step of the process, from sterile filling through secure bottling, boxing, wrapping, and distribution. We integrate years of proven fill-finish success with our own portfolio of FDA-approved products in manufacturing facilities that meet the most stringent regulatory criteria. Our ongoing relationships with suppliers and contractors ensure seamless and uninterrupted operations.
With ADMA Biologics as your dedicated contract manufacturing partner, you have 24-7 access to engineering, technical, and customer support while maintaining control of a consistent supply of commercial product lot releases. With enhanced speed of fill-finish functions calibrated to your production needs, we optimize the process from start to finish and streamline the complexities and minimize risks through the use of robotic aseptic filling systems.
ADMA Biologics possesses the unique capabilities and experience you need to ensure the highest standards of aseptic and sterile fill-finish processes. Our dedicated and highly-trained production, engineering, and scientific CMC teams work in real-time with our partners to design, integrate, and implement fill-finish solutions tailored to your specifications and therapeutic parameters:
1. Barahona Afonso AF, João CM. The production processes and biological effects of intravenous immunoglobulin. Biomolecules. 2016;6(1):15. Published 2016 Mar 9.
2. Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;6,431.